Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Immunovant

Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug

Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.

Investors Business Daily

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Investors Business Daily

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."

Investors Business Daily

Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump

Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.

Investors Business Daily

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.

Investors Business Daily

Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review

A stock market rally attempt started midweek, but it's not a confirmed uptrend yet. Nike, Costco, Amazon and Meta were newsmakers.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.

Investors Business Daily

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

Immunovant stock reversed lower Wednesday after the company announced a $300 million offering. IMVT stock almost doubled Tuesday.

Investors Business Daily

Immunovant Doubles — And Slugs Argenx — As Autoimmune Disease Battle Heats Up

Immunovant said Tuesday its experimental drug lowered an antibody tied to autoimmune diseases and IMVT stock launched.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022

Upgrades

Benzinga

Immunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This Year

Immunovant Inc (NASDAQ:IMVT) has aligned with the FDA Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 trials to evaluate batoclimab in thyroid eye disease (TED). Immunovant expects to initiate its Phase 3 TED program in 2H of 2022 and is expected to enroll about 100 subjects for each trial. Topline…

Benzinga

Immunovant: Q3 Earnings Insights

Immunovant (NASDAQ:IMVT) reported its Q3 earnings results on Friday, February 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations